Lipocine Inc. (LPCN)

NASDAQ: LPCN • USD
2.05 USD
-7.20 (-77.80%)
AT CLOSE (11:59 AM EDT)
2.05
+0.01 (+0.49%)
POST MARKET (AS OF 05:11 PM EDT)
🟢Market: OPEN
Open?$2.01
High?$2.11
Low?$1.81
Prev. Close?$9.25
Volume?7.2M
Avg. Volume?124.0K
VWAP?$2.11
Rel. Volume?57.91x
Bid / Ask
Bid?$1.75 × 100
Ask?$2.33 × 100
Spread?$0.58
Midpoint?$2.04
Valuation & Ratios
Market Cap?67.5M
Shares Out?7.3M
Float?5.2M
Float %?93.4%
P/E Ratio?N/A
P/B Ratio?4.66
EPS?-$1.32
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?6.68Strong
Quick Ratio?6.68Strong
Cash Ratio?2.06Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score
58/100
P/E?
N/A▾
P/B?
4.66FAIR▾
P/S?
34.16HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
-6.0CHEAP▾
EV/Sales?
31.53HIGH▾
Returns & Efficiency
ROE?
-66.5%WEAK▾
ROA?
-56.6%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$62.3M
Related Companies
Loading...
News
Profile
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Employees
14
Market Cap
67.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.lipocine.com
Listed
2012-06-05
Address
675 ARAPEEN DRIVE, SUITE 202
SALT LAKE CITY, X1 84108
Phone: 801 994 7383
MarketsMoversWatchlist